RNA interference: from gene silencing to gene-specific therapeutics.
about
Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivoMultifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimagingImproved targeting of miRNA with antisense oligonucleotidesSmall interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral productionHost gene targets for novel influenza therapies elucidated by high-throughput RNA interference screensNucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.MicroRNA regulation of human protease genes essential for influenza virus replicationGene-based therapy for hypertension--do preclinical data suggest a promising future?An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation.ING proteins as potential anticancer drug targets.RNA interference of pax2 inhibits growth of transplanted human endometrial cancer cells in nude mice.A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells.Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Modeling RNA interference in mammalian cellsSuppression of Mamu-AG by RNA interference.Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx miceInhibitory RNA molecules in immunotherapy for cancer.Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells.SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices.Lentiviral-mediated RNAi knockdown of Cbfa1 gene inhibits endochondral ossification of antler stem cells in micromass cultureAn RNAi in silico approach to find an optimal shRNA cocktail against HIV-1.Lipoplexes versus nanoparticles: pDNA/siRNA delivery.RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cellsGenetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity.Degradable polyelectrolyte multilayers that promote the release of siRNAModulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination.Gold nanorod--siRNA induces efficient in vivo gene silencing in the rat hippocampus.Variables and strategies in development of therapeutic post-transcriptional gene silencing agentsCombining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats.Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocolDesigned guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.Prospects of RNA interference therapy for cancer.Role of transforming growth factor-beta in hematologic malignanciesThe canonical Wnt signalling pathway and its APC partner in colon cancer development.Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapyRNA interference in pain research.siRNA efficiency: structure or sequence-that is the question.
P2860
Q21195224-A312A8B8-2862-4237-B3EA-44A89DA5C92CQ21223671-D6EDEBE4-1EE2-4423-9D29-64B0C94D17D7Q24547511-B5054B07-F371-4155-A6B8-7F4830E2E7CAQ24682936-2241B45E-0E54-450E-8826-6498B85F4CD9Q26852062-C306726B-7908-4CFE-B057-E0F6B4109220Q28085200-CD551FA1-D067-4B8D-88CF-8D8D8F13A00BQ28483683-38A37023-7C1C-47F3-BE8E-E503424BA11DQ31060643-1C91A951-9437-40E2-A96F-5316BD77DA52Q31066444-A8EE2AED-1BDA-488C-8A51-FB1B55BBDAF5Q33574029-2CB41E61-25A9-4FAD-A172-B2ECD75704FCQ33579715-663667E4-FAD9-4DC1-92B0-FE6C44B01B2BQ33598828-20ABCD1F-DE8D-481D-8805-7E6792855F42Q33635355-2C73ED79-A271-41F9-9EC2-70536C10DFB9Q33805528-A469223D-114B-49DC-B6D9-03CEA6C3D6C8Q33926798-49651ED5-127F-42FB-8754-96FB464A2B1CQ33931629-0C7B85B7-1471-4FAE-9A27-ABDAF4623137Q34033910-409E0799-53EF-42BE-8326-827D62A92591Q34087906-B78750A8-26CA-4228-846F-F6E73824C12FQ34177529-C277602E-B895-48DE-9C8F-DE4B91877B25Q34416043-39FA945D-384D-495A-BD0A-A7266ADB32D7Q34443061-0B68AF5D-C075-44A7-885D-F416D53F21A1Q34499103-DFD60388-0DBC-4A10-9A1D-BF1C70BE0772Q34640867-665B25EB-B2EB-49EE-BFE0-1F069FA0E85BQ34832425-473E59A0-BB3F-4729-8274-0A5D26727047Q35009319-3762E24C-D762-43C9-874E-48CFFACC93B3Q35046391-D5E50937-8C8F-4C16-88B8-E368DB29681AQ35066303-86F72C2E-B4A4-4204-AE17-789482CA10F7Q35093276-2D6C8507-2178-424A-88A9-68A34F38AB46Q35110219-9E0EAF1B-DF37-40E7-AD22-041978924410Q35326017-7057BCF8-795B-47CF-A533-25E51826B637Q35619078-B152C393-8D12-4034-8F4C-3D5633A0F9C6Q35688089-E816C9B6-9F14-4195-86E4-BAECC833AC2DQ36027056-4E7F5133-B7C7-44E4-950F-3DB0B657F277Q36170747-3E748DFB-CE3F-4315-90F6-C1DFCE8187FBQ36337922-9D4AE697-A9DA-461D-984F-6AF00219E9F1Q36399296-92E30927-FCE5-4545-8FF3-7B885CF39029Q36535617-C1115661-D6AD-4CB7-83B1-A3F463812C86Q36583404-2FB0891F-BFA6-43D0-B8D5-E9A883C4B584Q36618289-B2E66BB7-BC13-4706-B8A5-1AAE8C878F87Q36631549-6F31A03C-AC88-41F8-9E6C-D0E924FECE93
P2860
RNA interference: from gene silencing to gene-specific therapeutics.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
RNA interference: from gene silencing to gene-specific therapeutics.
@ast
RNA interference: from gene silencing to gene-specific therapeutics.
@en
type
label
RNA interference: from gene silencing to gene-specific therapeutics.
@ast
RNA interference: from gene silencing to gene-specific therapeutics.
@en
prefLabel
RNA interference: from gene silencing to gene-specific therapeutics.
@ast
RNA interference: from gene silencing to gene-specific therapeutics.
@en
P1476
RNA interference: from gene silencing to gene-specific therapeutics.
@en
P2093
Paul A Whittaker
Ray K M Leung
P304
P356
10.1016/J.PHARMTHERA.2005.03.004
P577
2005-08-01T00:00:00Z